MmuPV1 Infection and Tumor Development in T Cell-Deficient Mice Prevented by Passively Transferred Hyperimmune Sera from Normal Congenic Mice Immunized with MmuPV1 Virus-Like Particles

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.